Patients with cancers that have spread to the CNS or those at high risk for CNS involvement are potential candidates for intrathecal therapy. This includes individuals with certain types of leukemia, lymphoma, and metastatic solid tumors. The decision to use intrathecal therapy is based on a comprehensive evaluation of the patient's disease status, overall health, and treatment goals.
